Adding the menin inhibitor revumenib (Revuforj) to azacitidine and venetoclax (Venclexta) seemed to benefit older adults with ...

Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed ...

Pharmaceuticals announced that data from the BEAT AML trial of revumenib in combination with venetoclax and azacitidine in newly ...

The additional role of measurable residual disease 1 has been shown in many studies and different methods, including flow cytometry ... assessment, MRD monitoring can offer a valuable addition for ...

We report a 35-year-old male with AML who experienced relapse after multiple ... Post-chemotherapy bone marrow evaluation revealed 6.5% myeloblasts and minimal residual disease (MRD) of 3.8% by flow ...

To support physicians in treating cancer patients, oncology laboratories can benefit from adopting end-to-end automation of flow cytometry workflows. Rapid advances in automation are improving ...

Fluorescence-activated flow cytometry is one of the most powerful technologies that is routinely used in immunology. It allows not only for the rapid multiparametric analysis of cells on a cell-by ...

In a randomized phase 2 study of 79 patients with acute myeloid leukemia (AML ... included measurement of measurable residual disease (MRD) through ultrasensitive duplex DNA sequencing in 55 ...

Once submitted, we will try and place you in contact with a suitable Flow Cytometry Systems supplier within 48 hours.

“These results support the clinical benefit and tolerability of continuing ponatinib beyond cycle 3 in patients with newly diagnosed, Ph-positive ALL who do not achieve MRD-negativity by the end ...

A PROSPECTIVE study presented new evidence supporting the use of dual measurable residual disease (MRD) assessment, using both bone marrow flow cytometry and 18F-FDG PET/CT imaging, in evaluating ...